# Consolidated Basic Cancer Research Program

> **NIH CA P30** · WISTAR INSTITUTE · 2026 · $2,855,437

## Abstract

PROJECT SUMMARY – OVERALL
Rated Exceptional at both the 2013 (impact score, 19) and 2018 (impact score, 14) renewals of the Cancer
Center Support Grant (CCSG), and receiving a two-year MERIT extension from the National Cancer Institute
(NCI) in 2022, the Wistar Cancer Center continues an exponential path of research excellence. Leveraging a
deep-rooted culture of collaboration, a nearly complete equivalence between The Wistar Institute and the Cancer
Center, and a unified leadership structure where an experienced Cancer Center Director is also Institute
President and Chief Executive Officer, the Cancer Center functions as a catalyst for innovation in basic and
translational cancer research with broad societal impact. An unprecedented institutional commitment of over $81
million during the last five years enabled the recruitment of 17 new Cancer Center members at all academic
ranks, transformed the technological and scientific capabilities of all 8 CCSG-supported Shared Resources, and
strategically realigned Cancer Center Programs for maximal transdisciplinary collaboration with the launch of a
new Genome Regulation and Cell Signaling (GRCS) Program. The Wistar Cancer Center of 2025 comprises 32
members and has a total funding base of $14,610,429. Peer-reviewed, cancer-related funding stands at
$12,120,630 (83%), of which $6,765,960 is from the NCI translating into a strong cancer focus of 55%. As
collaboration is a foundational hallmark of the Cancer Center, 77% of peer-reviewed, cancer-related funding and
37% of discovery publications are the product of collaboration. Currently, Wistar is the only NCI-designated
“basic” Cancer Center to contribute to two Specialized Programs of Research Excellence (SPORE), three NCI
program project grants, two NCI consortium grants and twenty-nine multi-investigator R01 awards (22 from the
NCI, 76%). Building on these advances, the Cancer Center achieved unique societal impact during the last
CCSG budget period. Groundbreaking disc

## Key facts

- **NIH application ID:** 11333657
- **Project number:** 2P30CA010815-57
- **Recipient organization:** WISTAR INSTITUTE
- **Principal Investigator:** Dario C Altieri
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** CA
- **Fiscal year:** 2026
- **Award amount:** $2,855,437
- **Award type:** 2
- **Project period:** 1997-04-01T00:00:00 → 2031-02-28T00:00:00

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11333657

## Citation

> US National Institutes of Health, RePORTER application 11333657, Consolidated Basic Cancer Research Program (2P30CA010815-57). Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/grant/nih/11333657. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*